GLP-1 RECEPTOR AGONISTS HAVE A POTENTIAL TO IMPROVE DISEASE ACTIVITY IN PEDIATRIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

被引：0
|
作者：
Tou, Andrea [1 ]
Panganiban, Jennifer [1 ]
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
702
引用
收藏
页码：S519 / S520
页数：2
相关论文
共 50 条
  • [1] GLP-1 RECEPTOR AGONISTS HAVE A POTENTIAL TO IMPROVE DISEASE ACTIVTY IN PEDIATRIC METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE
    Tou, Andrea M.
    Panganiban, Jennifer
    GASTROENTEROLOGY, 2024, 166 (05) : S225 - S225
  • [2] Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
    Nowak, Klaudia
    Lupina, Krzysztof
    Romac, Anna
    Kalisz, Aleksandra
    Ilkiewicz, Lucja
    Janczura, Jakub
    ANNALS OF PHARMACOTHERAPY, 2025,
  • [3] GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Kanwal, Fasiha
    Kramer, Jennifer R.
    Li, Liang
    Yang, Yu-Xiao
    Cao, Yumei
    Yu, Xian
    Samuel, Ronald
    Ali, Basim
    Desiderio, Roxanne
    Cholankeril, George
    Bajaj, Mandeep
    El-Serag, Hashem B.
    Asch, Steven M.
    JAMA INTERNAL MEDICINE, 2024, 184 (11) : 1314 - 1323
  • [4] SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
    Moon, Jun Sung
    Hong, Jun Hwa
    Jung, Yong Jin
    Ferrannini, Ele
    Nauck, Michael A.
    Lim, Soo
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2022, 33 (06): : 424 - 442
  • [5] Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
    Huang, Xiaoyan
    Wu, Miaohui
    Huang, Baoliang
    Zhang, Yi
    FRONTIERS IN MEDICINE, 2025, 12
  • [6] Effects of Orforglipron, a novel oral GLP-1 receptor agonist, on metabolic dysfunction-associated steatotic liver disease related biomarkers
    Sanyal, A.
    Loomba, R.
    Lin, Y.
    Duffin, K.
    Wilson, J. M.
    Banerjee, H.
    Mather, K. J.
    Kazda, C.
    Konig, M.
    DIABETOLOGIA, 2024, 67 : S354 - S355
  • [7] Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy
    Kjeldsen, Sasha A. S.
    Gluud, Lise L.
    Werge, Mikkel P.
    Pedersen, Julie S.
    Bendtsen, Flemming
    Alexiadou, Kleopatra
    Tan, Tricia
    Torekov, Signe S.
    Iepsen, Eva W.
    Jensen, Nicole J.
    Richter, Michael M.
    Goetze, Jens P.
    Rungby, Jorgen
    Hartmann, Bolette
    Holst, Jens J.
    Holst, Birgitte
    Holt, Joachim
    Gustafsson, Finn
    Madsbad, Sten
    Svane, Maria S.
    Bojsen-Moller, Kirstine N.
    Albrechtsen, Nicolai J. Wewer
    ISCIENCE, 2023, 26 (11)
  • [8] Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes
    Havranek, Brandon
    Loh, Rebecca
    Torre, Beatriz
    Redfield, Rachel
    Halegoua-DeMarzio, Dina
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [9] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [10] Pharmacological management of pediatric metabolic dysfunction-associated steatotic liver disease
    Abou Jaoudeh, Rasha Abi Radi
    Hartmann, Phillipp
    Olson, Ole
    Gupta, Olga
    Kumar, Seema
    Ibrahim, Samar H.
    Fawaz, Rima
    Aqul, Amal
    Hassan, Sara
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2025, 80 (01): : 14 - 24
12345